MannKind Corporation (MNKD) News
Filter MNKD News Items
MNKD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MNKD News Highlights
- For MNKD, its 30 day story count is now at 8.
- Over the past 9 days, MNKD's stories per day has been in a clear uptrend, growing by about 0.23 per day.
- The most mentioned tickers in articles about MNKD are CONN, LUNG and NOV.
Latest MNKD News From Around the Web
Below are the latest news stories about MANNKIND CORP that investors may wish to consider to help them evaluate MNKD as an investment opportunity.
MannKind Corporation (NASDAQ:MNKD) Q3 2023 Earnings Call TranscriptMannKind Corporation (NASDAQ:MNKD) Q3 2023 Earnings Call Transcript November 7, 2023 MannKind Corporation beats earnings expectations. Reported EPS is $0.01, expectations were $-0.02. Operator: Good afternoon and welcome to the MannKind Corporation 2023 Third Quarter Financial Results Earnings Call. As a reminder, this call is being recorded on November 7th, 2023, and will be available […] |
MannKind (MNKD) Q3 2023 Earnings Call TranscriptAs a reminder, this call is being recorded on November 7, 2023, and will be available for playback on the MannKind Corporation website shortly after the conclusion of this call until November 21, 2023. Joining us today from MannKind are Chief Executive Officer Michael Castagna and Chief Financial Officer Steven Binder. |
MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to SayWhile the top- and bottom-line numbers for MannKind (MNKD) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
MannKind Corporation Reports 2023 Third Quarter Financial ResultsConference Call to Begin Today at 5:00 p.m. (ET) 3Q 2023 Total revenues of $51M; +56% vs. 3Q 20223Q YTD 2023 Total revenues of $140M; +121% vs. 3Q YTD 20223Q 2023 Net income of $2M; Non-GAAP net income of $4M3Q 2023 Tyvaso DPI royalties of $20M; +225% vs. 3Q 20223Q 2023 Endocrine BU net revenues of $18M; Afrezza net revenues +24% vs. 3Q 2022 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the |
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 DiabetesRapidly enrolled 141 patients in less than four monthsLarge study will compare A1c from baseline to 17 weeks for adults when switching from injectable insulin or pumps to inhaled insulin (Afrezza® (insulin human) Inhalation Powder)Initial standardized meal data from INHALE-3 on target for presenting in 1Q 2024 followed by primary endpoint analysis in 2Q 2024 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on th |
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseBiogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 third quarter financial results and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM (Eastern Time) on Tuesday, November 7, 2023. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, and Chief Financial Officer, Steven Binder. Those interested in |
MannKind Expands Patent Portfolio With New Clofazimine Formulation PatentPatent covers compositions of clofazimine, and methods for treating lung infectionsDevelopment of MNKD-101 (inhaled clofazimine) continues for the potential treatment of nontuberculous mycobacterial (NTM) lung disease DANBURY, Conn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced a new patent (No. 11,7 |
MannKind Corporation (NASDAQ:MNKD) is a favorite amongst institutional investors who own 53%Key Insights Given the large stake in the stock by institutions, MannKind's stock price might be vulnerable to their... |
7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue GrowthPharma stocks can be a great investment, particularly if they have solid performance, revenue growth and a positive outlook. |